PTEN and neoplasm: Thus, taking advantage of PARP inhibitor-induced cell death in PTEN-mutant glioma cells prone to genomic instability, and disabling survival pathways through EGFR and PARP inhibition, could be therapeutically exploited in the treatment of this malignant tumour.